Literature DB >> 12130930

Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?

Christian Junghanss1, Kieren A Marr.   

Abstract

PURPOSE OF REVIEW: Opportunistic infections contribute to morbidity and mortality after myeloablative allogeneic stem cell transplantation. The development of nonmyeloablative or toxicity-reduced conditioning regimens for allogeneic hematopoietic stem cell transplantation might change this picture significantly. These regimens are in general highly immunosuppressive, but effects on myelopoiesis and mucosal toxicities are usually reduced compared with myeloablative hematopoietic stem cell transplantation conditioning regimens. This review summarizes the infectious risks associated with each type of hematopoietic stem cell transplantation conditioning regimen, and presents the results of early clinical studies. RECENT
FINDINGS: Although the data are preliminary, the results of recent studies suggest that nonmyeloablative conditioning regimens may decrease the risks of bacterial infections associated with mucosal damage and persistent neutropenia; however, risks for late viral and fungal infections persist during severe graft versus host disease. Results of several case reports and series emphasize that therapeutic outcomes of infections may be improved in patients who receive nonmyeloablative conditioning regimens.
SUMMARY: Infectious risks and outcomes after hematopoietic stem cell transplantation appear to be in evolution given the introduction of alternative, nonmyeloablative conditioning regimens. Although infections remain a prominent cause of transplant-related mortality, the timing and types of infections may differ. Further studies are necessary to define appropriate preventative strategies, and to determine whether patients with ongoing infections might benefit from nonmyeloablative hematopoietic stem cell transplantation.

Entities:  

Mesh:

Year:  2002        PMID: 12130930     DOI: 10.1097/00001432-200208000-00001

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  6 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.

Authors:  J L Italia; M M Yahya; D Singh; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2009-02-13       Impact factor: 4.200

3.  Central nervous system infections in transplantation.

Authors:  Todd Czartoski
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

4.  Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan.

Authors:  Mohammad Faizan Zahid; Natasha Ali; Myra Nasir; Maria Haider Baig; Mustafa Iftikhar; Syed Usman Bin Mahmood; Arhama Malik; Sara Atif; Mohammad Asim Beg
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-14

5.  Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease.

Authors:  Pamela Paplham; Theresa Hahn; Karen Dubel; Patricia Lipka; Philip L McCarthy
Journal:  Leuk Res Rep       Date:  2014-04-18

6.  Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching.

Authors:  Sierra Jorge; Martino Rodrigo; García-Cadenas Irene; Esquirol Albert; Bosch-Vilaseca Anna; Awol Rahinatu; Novelli Silvana; Saavedra Silvana; Garrido Ana; López Jordi; Caballero Ana Carolina; Granell Miquel; Moreno Carolina; Briones Javier
Journal:  Bone Marrow Transplant       Date:  2020-10-26       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.